Working… Menu

A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 (IT-01)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03058289
Recruitment Status : Recruiting
First Posted : February 20, 2017
Last Update Posted : May 12, 2021
Merck Sharp & Dohme Corp.
Bristol-Myers Squibb
Information provided by (Responsible Party):
Intensity Therapeutics, Inc.

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : July 2022
Estimated Study Completion Date : October 2023